Open AccessLoteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
Author(s) -
Raymond Fong
Publication year - 2012
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s32643
Subject(s) - medicine , visual acuity , adverse effect , randomized controlled trial , cataract surgery , intraocular pressure , ophthalmology , surgery , anesthesia
Loteprednol etabonate (LE) is approved by the US FDA in a suspension and ointment form (0.5%) for the treatment of postoperative ocular inflammation. This study examined the gel formulation of LE, an improved, nonsettling formulation with a lower preservative level and a more physiologic pH.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom